<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <title>Project Charter – Irish Biologics Expansion</title>
    <link rel="stylesheet" href="../../assets/style.css">
    <meta name="viewport" content="width=device-width, initial-scale=1">
</head>

<body>

    <nav>
        <a href="../../index.html" class="logo">Kshama</a>
        <div class="nav-links">
            <a href="../../about.html">About</a>
            <a href="../../resources.html">Resources</a>
        </div>
    </nav>

    <header class="hero">
        <h1>Project Charter</h1>
        <p class="subtitle">Formal programme mandate, strategic alignment and governance approval framework</p>
    </header>

    <main>
        <section class="content-card">

            <h2>1. Programme Background</h2>

            <p>
                The West Dublin manufacturing campus operates a sterile biologics facility supplying EU and US markets.
                Site utilisation exceeded 90% capacity following expanded therapeutic indication approval
                for a high-volume monoclonal antibody product.
            </p>

            <p>
                Network capacity analysis identified upstream bioreactor constraints and downstream purification
                bottlenecks,
                creating a projected 18–24 month supply risk without expansion.
            </p>

            <p>
                The expansion programme was initiated to protect commercial continuity,
                maintain regulatory compliance, and secure long-term manufacturing resilience.
            </p>

            <h2>2. Strategic Alignment</h2>

            <ul>
                <li>Supports Global Manufacturing 5-Year Capacity Strategy</li>
                <li>Protects €180M annual EU revenue stream</li>
                <li>Improves supply continuity risk index by 22%</li>
                <li>Strengthens Ireland’s role as EU biologics centre of excellence</li>
                <li>Aligns with regulatory quality maturity roadmap</li>
            </ul>

            <h2>3. Business Case Summary</h2>

            <div class="table-wrap">
                <table>
                    <tr>
                        <th>Capital Investment</th>
                        <td>€180 Million</td>
                    </tr>
                    <tr>
                        <th>Capacity Increase</th>
                        <td>+38% Upstream Output</td>
                    </tr>
                    <tr>
                        <th>Revenue Protection</th>
                        <td>€180M Annually</td>
                    </tr>
                    <tr>
                        <th>Break-even Period</th>
                        <td>3.5 Years</td>
                    </tr>
                    <tr>
                        <th>Net Present Value</th>
                        <td>Positive (Confidential)</td>
                    </tr>
                    <tr>
                        <th>Inspection Requirement</th>
                        <td>EU GMP + FDA Approval</td>
                    </tr>
                </table>
            </div>

            <h2>4. Programme Objectives</h2>

            <ul>
                <li>Install two 20,000L stainless steel upstream bioreactors</li>
                <li>Expand downstream purification capacity</li>
                <li>Extend ISO 7 cleanroom footprint</li>
                <li>Upgrade utilities (WFI, Clean Steam, HVAC)</li>
                <li>Deliver full Commissioning, Qualification & Validation (CQV)</li>
                <li>Achieve regulatory approval within planned inspection window</li>
                <li>Maintain uninterrupted commercial production during works</li>
            </ul>

            <h2>5. Scope Definition</h2>

            <p><strong>In Scope:</strong></p>
            <ul>
                <li>Engineering Design (URS → FDS → Detailed Design)</li>
                <li>Construction in live GMP environment</li>
                <li>Long-lead equipment procurement & FAT</li>
                <li>Automation integration & Computer System Validation</li>
                <li>Full IQ/OQ/PQ lifecycle execution</li>
                <li>Inspection readiness preparation</li>
            </ul>

            <p><strong>Out of Scope:</strong></p>
            <ul>
                <li>Process development modifications</li>
                <li>Global supply chain redesign</li>
                <li>Commercial packaging line expansion</li>
            </ul>

            <h2>6. Governance Structure</h2>

            <ul>
                <li>Executive Sponsor – Global Manufacturing VP</li>
                <li>Site Sponsor – Ireland Operations Director</li>
                <li>Programme Director – Capital Programmes Office</li>
                <li>QA Lead – Site Qualified Person Representative</li>
                <li>Regulatory Liaison – HPRA Engagement Lead</li>
                <li>Financial Oversight – Corporate Capital Review Board</li>
            </ul>

            <h2>7. Stakeholder Matrix</h2>

            <div class="table-wrap">
                <table>
                    <tr>
                        <th>Stakeholder</th>
                        <th>Role</th>
                        <th>Influence</th>
                        <th>Engagement Model</th>
                    </tr>
                    <tr>
                        <td>Global Manufacturing</td>
                        <td>Capital Approval Authority</td>
                        <td>High</td>
                        <td>Monthly Executive Review</td>
                    </tr>
                    <tr>
                        <td>Site Operations</td>
                        <td>Production Continuity</td>
                        <td>High</td>
                        <td>Weekly Steering</td>
                    </tr>
                    <tr>
                        <td>Quality Assurance</td>
                        <td>Compliance Oversight</td>
                        <td>High</td>
                        <td>Risk Committee Cadence</td>
                    </tr>
                    <tr>
                        <td>Engineering & Automation</td>
                        <td>Technical Delivery</td>
                        <td>Medium</td>
                        <td>Integrated Master Schedule Governance</td>
                    </tr>
                    <tr>
                        <td>Regulatory Authorities</td>
                        <td>Inspection Approval</td>
                        <td>Critical</td>
                        <td>Pre-inspection Engagement</td>
                    </tr>
                </table>
            </div>

            <h2>8. Assumptions</h2>

            <ul>
                <li>Regulatory inspection window remains fixed within Month 23–24</li>
                <li>Vendor delivery timelines maintained within contractual tolerance</li>
                <li>No significant GMP interpretation changes during build phase</li>
                <li>Utilities capacity modelling remains accurate within ±5% margin</li>
            </ul>

            <h2>9. Constraints</h2>

            <ul>
                <li>Live GMP environment limits construction windows</li>
                <li>Highly specialised CQV labour market in Ireland</li>
                <li>Strict change control governance during PQ phase</li>
                <li>Fixed capital approval ceiling (€180M)</li>
            </ul>

            <h2>10. Milestone Plan</h2>

            <div class="table-wrap">
                <table>
                    <tr>
                        <th>URS Approval</th>
                        <td>Month 3</td>
                    </tr>
                    <tr>
                        <th>Detailed Design Freeze</th>
                        <td>Month 6</td>
                    </tr>
                    <tr>
                        <th>Equipment FAT Complete</th>
                        <td>Month 12</td>
                    </tr>
                    <tr>
                        <th>Mechanical Completion</th>
                        <td>Month 17</td>
                    </tr>
                    <tr>
                        <th>IQ/OQ Execution Complete</th>
                        <td>Month 20</td>
                    </tr>
                    <tr>
                        <th>PQ Complete</th>
                        <td>Month 22</td>
                    </tr>
                    <tr>
                        <th>Regulatory Inspection</th>
                        <td>Month 23</td>
                    </tr>
                    <tr>
                        <th>Commercial Release</th>
                        <td>Month 24</td>
                    </tr>
                </table>
            </div>

            <h2>11. Critical Success Metrics</h2>

            <ul>
                <li>Zero production interruption events</li>
                <li>Schedule variance within ±3%</li>
                <li>Budget variance within approved contingency limits</li>
                <li>0 Critical regulatory findings</li>
                <li>Go-live achieved within regulatory booking window</li>
            </ul>

            <h2>12. Approval</h2>

            <p>
                This charter represents formal authorisation to proceed with the capital programme
                subject to stage-gate financial governance and regulatory compliance requirements.
            </p>

        </section>
    </main>

    <footer>© 2026 Kshama</footer>
</body>

</html>